[Comparative evaluation of 2 schedules of administration of anti- neoplastic drugs by the CMF protocol in disseminated breast cancer]. / Sravnitel'naia otsenka dvukh rezhimov vvedeniia protivoopukholevykh preparatov po skheme CMF pri disseminirovannom rake molochnoi zhelezy.

Combined chemotherapy with cyclophosphamide, methotrexate, fluorouracil (CMF) in two regimens of administration was comparatively assessed in a randomized and prospective trial. Group I patients (n = 34) received methotrexate and fluorouracil once a week and cyclophosphamide every other day for 15 days. In group II (n = 32) all the drugs were given simultaneously once weekly for 15 days. A complete and partial response occurred significantly more frequently in patients of group I (36%) versus group II (7%). The intergroup difference in toxicity appeared insignificant.

[Use of adriablastine in the combined chemotherapy of breast cancer patients with bone metastases]. / Primenenie adriablastina v kombinirovannoi khimioterapii bol'nykh s kostnymi metastazami raka molochnoi zhelezy.

Twenty patients with generalized breast cancer metastasizing in bones were subjected to treatment by a combination of adriablastine with cyclophosphane or adriablastine with cyclophosphane, 5-fluoruracil, vincristine using repeat 8-day cycles with 3-week intervals between them. A considerable subjective and sympathetic improvement was noted in 13 patients. Of 14 patients in whom bone metastases were associated with tumor involvement of different soft tissues and organs the tumor regression was gained in 8 patients. Side effects in all these cases were similar and mostly related with the use of adriablastine: nausea, vomiting, alopecia.